NAUTILUS" BIOTECHNOLOGY Delivering on the Promise of the Proteome OCTOBER 29, 2024 Safe harbor This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the protein analysis market; Nautilus Biotechnology's anticipated total addressable market; the performance, value and enabling nature of Nautilus Biotechnology's proteomics and pr ...

Financial Performance - Net loss for Q3 2024 was $16.4 million, compared to a net loss of $15.9 million in Q3 2023[4] - Operating expenses for Q3 2024 were $19.1 million, flat compared to Q3 2023[3] - The company reported a net cash used in operating activities of $44.8 million for the nine months ended September 30, 2024, compared to $37.8 million for the same period in 2023[15] Cash and Investments - Cash, cash equivalents, and investments totaled $221.2 million as of September 30, 2024[4] - Cash, cash equivalents, and restricted cash at the end of the period were $5.4 million, down from $75.1 million at the end of Q3 2023[15] Expenses - Research and development expenses for Q3 2024 were $12.3 million, up from $12.0 million in Q3 2023[13] - General and administrative expenses for Q3 2024 were $6.8 million, down from $7.1 million in Q3 2023[13] Assets and Liabilities - Total assets decreased to $259.7 million as of September 30, 2024, from $305.6 million at the end of 2023[11] - Total liabilities decreased to $36.3 million as of September 30, 2024, from $40.2 million at the end of 2023[11] Strategic Focus - The company is focused on advancing its single-molecule proteome analysis platform, which is expected to enhance research capabilities in proteomics[2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-1541723 ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tycho Peterson - Jefferies Dan Brennan - TD Cowen Operator Good day and thank you for standing by and welcome to Nautilus Q2 2024 Earnings Conference Call. [Operator Inst ...

Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2024 Financial Results SEATTLE, WA, July 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single- molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. "In Q2, we saw continued progress against core development goals for each of the components of our platform," said Sujal Patel, CEO of Nautilus. "We believe we are pioneering a fundamentally new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Address of principal executive offices) (Zip Code) (206) 333-2001 (Regis ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be ...

Exhibit 99.1 Nautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, WA, April 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. "We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus. "We remain incredibly focused on increasing the scale, stability, and reproducibil ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good day, and thank you for standing by. Welcome to Nautilus Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact nam ...